COMMUNIQUÉS West-GlobeNewswire

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
16/06/2026
Intellectual property update confirms pelareorep’s unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings [...]
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
16/06/2026
Pre-production, Engineering Run and GMP Manufacture of PRP in 2026 MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company [...]
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
16/06/2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, [...]
GHK-Cu For Sale At Koi Peptides for Laboratory Use in 2026
16/06/2026
SHERIDAN, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides has launched GHK-Cu, the copper tripeptide-1 complex that forms when copper(II) binds glycyl-L-histidyl-L-lysine (a tripeptide), as a research-use-only [...]
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
16/06/2026
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by mid-July 2026, with [...]
NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure
16/06/2026
NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure Settlement to eliminate potential dilution from convertible notes [...]
CDT Equity Announces Debt Update and New Loan Facility
16/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all [...]
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
16/06/2026
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. ( [...]
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
16/06/2026
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which [...]
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
16/06/2026
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 [...]
Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
16/06/2026
The agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than 2,000 government facilities, including those administered by the U.S. Department of Veterans Affairs, the [...]
Klow Peptide Stack Introduced by Koi Peptides for Laboratory Research in 2026
16/06/2026
Sheridan, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has introduced Klow Peptide Stack as a research-use-only multi-peptide blend for laboratory research in 2026. The product contains GHK [...]
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
16/06/2026
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard [...]
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
16/06/2026
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary [...]
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
16/06/2026
Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research MINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused [...]
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
16/06/2026
IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE [...]
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
16/06/2026
Urges Stockholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 16, 2026 ( [...]
ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome
16/06/2026
RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptoms in rare [...]
Sanuwave Health Updates Second Quarter 2026 Guidance
16/06/2026
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE [...]

Pages